Positions
- Associate Professor
-
Pediatrics-Tropical Medicine
Baylor College of Medicine
Houston, TX, US
- Faculty Senator
-
Baylor College of Medicine
Addresses
- TX Childs Feigin Ctr (Office)
-
Room: TXFC-C1470.34
Houston, TX, 77030
United States
Phone: (832) 824-0502
strych@bcm.edu
Education
- PhD from Ruhr University
- 05/1995 - Bochum, NRW, Germany
- MS from Ruhr University
- 05/1991 - Bochum, NRW, Germany
Websites
Selected Publications
-
McCarty M, Hernández SA, Malfetano J, Leão AC, Villar MJ, Yang X, Chen YL, Lee J, Liu Z, Strych U, Bottazzi ME, Pal U, Strle K, Chen WH, Lin YP.. " Developing a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rationale adjuvant selection " NPJ Vaccines. 2026 ;
Pubmed PMID: 42143044. -
Hotez PJ, Adhikari R, Chen WH, Chen YL, Gillespie P, Islam NY, Keegan B, Tyagi Kundu R, Lee J, Liu Z, Kimata JT, Oezguen N, Pollet J, Poveda C, Razavi K, Ronca SE, Strych U, Thimmiraju SR, Versteeg L, Villar-Mondragon MJ, Wei J, Zhan B, Bottazzi ME.. " From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. " Expert Review of Vaccines. 2023 ;
Pubmed PMID: 37252854. -
Bartsch SM, Chin KL, Strych U, John DC, Shah TD, Bottazzi ME, O'Shea KJ, Robertson M, Weatherwax C, Heneghan J, Martinez MF, Ciciriello A, Kulkarni S, Velmurugan K, Dibbs A, Scannell SA, Shen Y, Nash D, Hotez PJ, Lee BY.. " The Current and Future Burden of Long COVID in the United States. " Journal of Infectious Diseases. 2025 ;
Pubmed PMID: 39842946.
Intellectual Property
- Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
- Product Patent #WO 2005020973 A2 (Approved)
- This invention relates to a group of compounds with anti-mycobacterial activities that have a common hydroxamic acid structural feature and to methods for using same. This invention also relates to compositions including an hydroxamate and an hydroxylamine which possess anti-mycobacterial activity and to methods for making and using same. [0002] More particularly, the present invention relates to compositions capable of inhibiting mycobacterium tuberculosis in standard mycobacterial growth assays, where the compositions include a therapeutically effective amount of an hydroxamate or an therapeutically effective amount of an hydroxamate and an hydroxylamine and to methods for using same.
- Co Inventors: Michael Benedik, James M Briggs, Myoung Goo Kim, Harold Kohn, Kurt L Krause
Log In to edit your profile